LES PHAGES DANS LES IOA **De l'historique aux indications pertinentes**

Pr. Tristan Ferry tristan.ferry@univ-lyon1.fr

Infectious and Tropical Diseases Unit Croix-Rousse Hospital, Hospices Civils de Lyon Claude Bernard Lyon1 University, Lyon

Centre International de Recherche en Infectiologie, CIRI, Inserm U1111, CNRS UMR5308, ENS de Lyon, UCBL1, Lyon, France

Centre de Référence des IOA complexes de Lyon (CRIOAc Lyon)









What is a « bacteriophage » ?

- Suffix –phage, phagos φαγεῖν (phagein), "to eat", "to devour"
- Viruses that infect ONLY bacteria
- Classification (*myoviridae*, *podoviridae*, *etc...*)
- <u>A phage is specific to A type of bacteria</u>
- Largely abundant in the biosphere: 10³¹ bacteriophages on the planet, more than every other organism
- Especially in marine environment, sea, lake, backwater, soil, animal and human stools, etc.







10 to 100 fold smaller than a bacteria

Translucent tap water




X million of ≠ Bactériophage<u>S</u> !!! (targeting environmental bacteria)




10⁸ of THREE bacteriophages/mL (targeting *S. aureus*)






Ferry T.




Lysogenic cycle

Ferry T.




Lysogenic cycle

Ferry T.




Self-maintained bacterial lysis





Self-maintained bacterial lysis







- Felix d'Herelle
- Institut Pasteur, Paris







- Felix d'Herelle
- Institut Pasteur, Paris
- He treated <u>shigellosis</u> (diarrhea) in children with <u>oral intake</u> of specific "filtered" <u>bacteriophages</u> that he found in stools of patients who spontaneously healed from... shigellosis







- Felix d'Herelle
- Institut Pasteur, Paris
- He treated <u>shigellosis</u> (diarrhea) in children with <u>oral intake</u> of specific "filtered" <u>bacteriophages</u> that he found in stools of patients who spontaneously healed from... shigellosis
- He founded <u>Eliava institute in Georgia</u> and the <u>"Laboratoire Français des</u> <u>Bactériophages"</u> in Paris





Docteur André RAIGA

Ancien Interne lauréat des Hôpitaux Ex-Chef de Clinique chirurgicale à la Faculté

H 10 H

At the stage of bone necrosis, **it will only succeed in stopping the progression of the infection**, but **it will be able to do nothing against the dead bone deprived of circulation; this bone will become sequestered and the lesion is no longer a matter of surgery.** To do otherwise is to commit, in my opinion, an error of therapeutic indication.

Au stade de nécrose osseuse, il ne réussira plus qu'à enrayer la progression de l'infection, mais il ne pourra plus rien contre l'os que la mort a privé de circulation ; cet os va se séquestrer et la lésion ne relève plus maintenant que de la chirurgie. Agir autrement c'est commettre, à mon sens, une erreur d'indication thérapeutique. 1961



Docteur André RAIGA

Ancien Interne lauréat des Hópitaux Ex-Chef de Clinique chirurgicale à la Faculté

H 10 H

At the stage of bone necrosis, **it will only succeed in stopping the progression of the infection**, but **it will be able to do nothing against the dead bone deprived of circulation; this bone will become sequestered and the lesion is no longer a matter of surgery.** To do otherwise is to commit, in my opinion, an error of therapeutic indication.

Au stade de nécrose osseuse, il ne réussira plus qu'à enrayer la progression de l'infection, mais il ne pourra plus rien contre l'os que la mort a privé de circulation ; cet os va se séquestrer et la lésion ne relève plus maintenant que de la chirurgie. Agir autrement c'est commettre, à mon sens, une erreur d'indication thérapeutique. 1961


Le Journal de Médecine de Lyon

After d'Herelle, the story continued in Lyon


Traitement des infections à bacilles pyocyaniques par des bactériophages adaptés par sélection.

Par MM. André BERTOYE et A.-L. COURTIEU.





Clinique des Maladies Infectieuses, Hôpital de la Croix-Rousse Hospices Civils de Lyon 1958-1960



Bactériophages thérapeutiques préparés à l'Institut Pasteur de Lyon dans les années 1970

Academic collaboration 70 patients/year!

Pr. Bertoye

Pathogenic bacteria from the patient

978

Infectious Disease clinic

Institut Pasteur

Lyon

Active and trained


bacteriophages



Large production of antibiotics in 1970-1980 killed the phage therapy

- Industrial production
- Large spectrum
- Bactericidal activity
- Oral and IV
- <u>Systemic diffusion</u> to the infected site
- Numerous <u>different</u>
 <u>kinds of families</u>,


with different mechanism of action



Large production of antibiotics in 1970-1980 killed the phage therapy

- Industrial production
- Large spectrum
- Bactericidal activity
- Oral and IV
- <u>Systemic diffusion</u> to the infected site
- Numerous <u>different</u>
 <u>kinds of families</u>,

with different mechanism of action






<u>Complex virus</u>-based <u>personalized</u> treatment without clear industrial process, <u>not considered as a drug</u>

Large production of antibiotics in 1970-1980 killed the phage therapy

- Industrial production
- Large spectrum
- Bactericidal activity
- Oral and IV
- <u>Systemic diffusion</u> to the infected site
- Numerous <u>different</u>
 <u>kinds of families</u>,

with different mechanism of action






<u>Complex virus</u>-based <u>personalized</u> treatment without clear industrial process, <u>not considered as a drug</u>

Large production of antibiotics in 1970-1980 killed the phage therapy

- Industrial production
- Large spectrum Phages as the Phoenix?
- **Bactericidal** activity
- Oral and IV
- Systemic diffusion to the infected site
- Numerous different kinds of families,

with different mechanism of actions






<u>Complex</u> <u>virus</u>-based <u>personalized</u> treatment without clear industrial ss, not considered as a drug

Cocktails produced in 2020 by the Eliava Institute

- PYO Bacteriophage
- FERSIS Bacteriophage
- STAPHYLOCOCCAL Bacteriophage
- SES Bacteriophage
- INTESTI Bacteriophage
- ENKO Bacteriophage




Bacteriophage ISP (Myoviridae)



Merabishvili et al. PloS ONE 2009

T. Ferry. The story of Phage therapy

Not meeting Good Manufacturing Practices (GMP)



Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by *Pseudomonas aeruginosa* (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial











REFERENCE CENTERS FOR THE MANAGEMENT OF BONE AND JOINT INFECTION



Adapted from Ferry T, et al. Orthop Traumatol Surg Res. 2019;105(1):185-190

REFERENCE CENTERS FOR THE MANAGEMENT OF BONE AND JOINT INFECTION



Adapted from Ferry T, et al. Orthop Traumatol Surg Res. 2019;105(1):185-190

Declaration of Helsinki



Special Communication

World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects



Wori d

MEDICAL

World Medical Association

- Unproven Interventions in Clinical Practice
- 37. In the treatment of an individual patient, where proven interventions do not exist or other known interventions have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorised representative, <u>May use</u> an <u>Unproven</u> intervention if in the physician's judgement it offers hope of <u>saving life</u>, <u>re-establishing health</u> or alleviating suffering. In France: <u>compassionate</u> use, magistral preparation by the hospital pharmacist

Partial bone necrosis requiring <u>surgery</u>

Skin and soft tissue damage requiring <u>surgical coverage</u>



MAJOR BIOLOGICAL LIMIT:

Bacteriophages <u>have not the</u> <u>capacity</u> to perform bone debridement nor to regenerate skin and sof tissue



Patient with a relapsing infection after Phage therapy in Tbilissi

Clinical case #4


80-year-old man

<u>**Relapsing MSSA</u>** prosthetic left knee infection (past revision)</u>

Failure under suppressive oral antimicrobial therapy

Complex orthopaedic situation with past femoral fracture

Impossible to walk (painful knee)







Clinical case #4

Amputation (but not feasible !) ?




Doing nothing, but poor clinical situation with <u>risk of</u> complication and death


Conservative surgery


"Debridement And Implant Retention" (DAIR) + <u>innovative approach to</u> <u>disrupt biofilm</u> + suppressive antimicrobial therapy ?



Lyon Phage team




















"Debridement And Implant Retention" (DAIR)





"PhagoDAIR"



One shot peroperative phage application after "DAIR"



Clinical case #4

Post-operative antibiotics:

Daptomycin + Rifampin

<u>At day 4 (only MSSA in all intraoperative samples):</u>

Levofloxacin + Rifampin

<u>Then:</u>

Cefalexin as suppressive antimicrobial therapy









"The bacteriophages saved my life, he insists. I never thought one day to walk again. And to say that doctors were talking about cutting my leg off!" R.N.



 Crucial need for (alternatives) <u>additional therapies</u> <u>to antibiotics</u> to maximize clinical success in complex bacterial infections





- Crucial need for (alternatives) <u>additional therapies</u> <u>to antibiotics</u> to maximize clinical success in complex bacterial infections
- Phage therapy is a <u>Phoenix</u>
- Don't forget <u>Lessons from 20th century</u>







- Crucial need for (alternatives) <u>additional therapies</u> <u>to antibiotics</u> to maximize clinical success in complex bacterial infections
- Phage therapy is a <u>Phoenix</u>
- Don't forget <u>Lessons from 20th century</u>
- Develop and use <u>GMP bacteriophages</u> (phages 2.0) ▶ <u>19 patients treated in 2 years</u>
- Industry / health authority / academic <u>collaborations</u>










- Crucial need for (alternatives) <u>additional therapies</u> <u>to antibiotics</u> to maximize clinical success in complex bacterial infections
- Phage therapy is a <u>Phoenix</u>
- Don't forget <u>Lessons from 20th century</u>
- Develop and use <u>GMP bacteriophages</u> (phages 2.0) ▶ <u>19 patients treated in 2 years</u>
- Industry / health authority / academic <u>collaborations</u>
- Reference (regional or national) clinical centers to determine relevant indications
- Need for <u>Phage</u> <u>discovery</u>, <u>banking</u>, <u>susceptibility</u>, to personalize the therapy









- Crucial need for (alternatives) <u>additional therapies</u> <u>to antibiotics</u> to maximize clinical success in complex bacterial infections
- Phage therapy is a <u>Phoenix</u>
- Don't forget <u>Lessons from 20th century</u>
- Develop and use <u>GMP bacteriophages</u> (phages 2.0) ▶ <u>19 patients treated in 2 years</u>
- Industry / health authority / academic <u>collaborations</u>
- Reference (regional or national) clinical centers to determine relevant indications
- Need for <u>Phage discovery</u>, <u>banking</u>, <u>susceptibility</u>, to personalize the therapy
- Need for national phage therapy center(s)





